130 related articles for article (PubMed ID: 24138719)
1. Anti-angiogenic drugs and biomarkers in non-small-cell lung cancer: a 'hard days night'.
Pilotto S; Bonomi M; Massari F; Milella M; Ciuffreda L; Brunelli M; Fassan M; Chilosi M; Scarpa A; Tortora G; Bria E
Curr Pharm Des; 2014; 20(24):3958-72. PubMed ID: 24138719
[TBL] [Abstract][Full Text] [Related]
2. Combining anti-Epidermal Growth Factor Receptor (EGFR) and anti-angiogenic strategies in advanced NSCLC: we should have known better….
Di Maio M; Morabito A; Piccirillo MC; Daniele G; Giordano P; Costanzo R; Sandomenico C; Montanino A; Rocco G; Perrone F
Curr Pharm Des; 2014; 20(24):3901-13. PubMed ID: 24191956
[TBL] [Abstract][Full Text] [Related]
3. An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
Pilotto S; Novello S; Peretti U; Kinspergher S; Ciuffreda L; Milella M; Carbognin L; Vavalà T; Ferrara R; Caccese M; Tortora G; Bria E
Expert Opin Investig Drugs; 2015; 24(9):1143-61. PubMed ID: 26065529
[TBL] [Abstract][Full Text] [Related]
4. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.
Farhat FS; Tfayli A; Fakhruddin N; Mahfouz R; Otrock ZK; Alameddine RS; Awada AH; Shamseddine A
Crit Rev Oncol Hematol; 2012 Nov; 84(2):149-60. PubMed ID: 22494932
[TBL] [Abstract][Full Text] [Related]
5. [Targeted therapies in non-small cell lung cancer in 2014].
Leduc C; Besse B
Rev Mal Respir; 2015 Feb; 32(2):182-92. PubMed ID: 25704901
[TBL] [Abstract][Full Text] [Related]
6. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.
Pircher A; Jöhrer K; Kocher F; Steiner N; Graziadei I; Heidegger I; Pichler R; Leonhartsberger N; Kremser C; Kern J; Untergasser G; Gunsilius E; Hilbe W
Oncotarget; 2016 Apr; 7(15):20109-23. PubMed ID: 26956051
[TBL] [Abstract][Full Text] [Related]
8. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
Skouras VS; Maragkos C; Grapsa D; Syrigos KN
BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of non-small cell lung cancer (NSCLC): time to "work it out"?
Galvani E; Toffalorio F; Peters GJ; De Pas T; Giovannetti E
Curr Pharm Des; 2014; 20(24):3863-74. PubMed ID: 24138720
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).
Franzini A; Baty F; Macovei II; Dürr O; Droege C; Betticher D; Grigoriu BD; Klingbiel D; Zappa F; Brutsche MH
Clin Cancer Res; 2015 Dec; 21(23):5253-63. PubMed ID: 25922429
[TBL] [Abstract][Full Text] [Related]
11. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Li F; Zhu T; Cao B; Wang J; Liang L
Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
[TBL] [Abstract][Full Text] [Related]
12. Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions.
Ellis PM; Al-Saleh K
Crit Rev Oncol Hematol; 2012 Oct; 84(1):47-58. PubMed ID: 22405734
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of motesanib diphosphate in non-small-cell lung cancer.
Rijavec E; Genova C; Barletta G; Biello F; Dal Bello MG; Coco S; Truini A; Vanni I; Alama A; Boccardo F; Grossi F
Expert Opin Pharmacother; 2014 Aug; 15(12):1771-80. PubMed ID: 25032887
[TBL] [Abstract][Full Text] [Related]
14. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
15. [Anti-angiogenic strategy: therapy optimization of non-squamous non-small cell lung carcinoma].
Reinmuth N; Reck M; Grohé C
Pneumologie; 2014 Dec; 68(12):793-8. PubMed ID: 25489867
[TBL] [Abstract][Full Text] [Related]
16. Pericytes from human non-small cell lung carcinomas: an attractive target for anti-angiogenic therapy.
Bagley RG; Rouleau C; Morgenbesser SD; Weber W; Cook BP; Shankara S; Madden SL; Teicher BA
Microvasc Res; 2006 May; 71(3):163-74. PubMed ID: 16624341
[TBL] [Abstract][Full Text] [Related]
17. Management and future directions in non-small cell lung cancer with known activating mutations.
Gerber DE; Gandhi L; Costa DB
Am Soc Clin Oncol Educ Book; 2014; ():e353-65. PubMed ID: 24857124
[TBL] [Abstract][Full Text] [Related]
18. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
Trials; 2015 Apr; 16():146. PubMed ID: 25873045
[TBL] [Abstract][Full Text] [Related]
19. [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
Hamard C; Ruppert AM; Lavole A; Rozensztajn N; Antoine M; Cadranel J; Wislez M
Ann Pathol; 2016 Jan; 36(1):63-72. PubMed ID: 26775573
[TBL] [Abstract][Full Text] [Related]
20. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.
Van der Veldt AA; Lubberink M; Bahce I; Walraven M; de Boer MP; Greuter HN; Hendrikse NH; Eriksson J; Windhorst AD; Postmus PE; Verheul HM; Serné EH; Lammertsma AA; Smit EF
Cancer Cell; 2012 Jan; 21(1):82-91. PubMed ID: 22264790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
